Pulse Biosciences (NASDAQ:PLSE) Stock Price Up 6.2% – Still a Buy?

Pulse Biosciences, Inc (NASDAQ:PLSE) shares were up 6.2% on Monday. The company traded as high as $47.61 and last traded at $47.1770. Approximately 139,102 shares were traded during trading, a decline of 64% from the average session volume of 390,397 shares. The stock had previously closed at $44.43.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on PLSE shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Thursday. Needham & Company LLC assumed coverage on Pulse Biosciences in a research report on Monday, August 17th. They set a “buy” rating and a $58.00 price target for the company. BTIG Research initiated coverage on Pulse Biosciences in a research report on Wednesday, September 23rd. They set a “buy” rating and a $70.00 price target for the company. Oppenheimer boosted their price target on Pulse Biosciences from $35.00 to $60.00 and gave the stock an “outperform” rating in a report on Tuesday, October 13th. Finally, Mizuho set a $55.00 price objective on Pulse Biosciences in a research report on Tuesday, October 13th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Pulse Biosciences currently has an average rating of “Moderate Buy” and an average target price of $60.20.

Pulse Biosciences Price Performance

The firm has a market cap of $3.34 billion, a price-to-earnings ratio of -39.95 and a beta of 1.57. The business’s 50-day moving average price is $49.82 and its two-hundred day moving average price is $34.43.

Pulse Biosciences (NASDAQ:PLSE) last announced its earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07). The firm had revenue of $0.43 million for the quarter, compared to analyst estimates of $0.53 million. Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%. As a group, sell-side analysts forecast that Pulse Biosciences, Inc will post -1.34 earnings per share for the current year.

Insider Buying and Selling

In other Pulse Biosciences news, COO Liane Teplitsky bought 1,036 shares of Pulse Biosciences stock in a transaction that occurred on Wednesday, August 26th. The shares were purchased at an average cost of $48.23 per share, for a total transaction of $49,966.28. Following the completion of the transaction, the chief operating officer owned 1,036 shares of the company’s stock, valued at $49,966.28. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders acquired 4,095 shares of company stock valued at $199,931 in the last ninety days. Corporate insiders own 74.00% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of PLSE. Formula Growth Ltd. acquired a new stake in shares of Pulse Biosciences in the second quarter worth approximately $832,000. Panoramic Capital LLC purchased a new stake in Pulse Biosciences in the second quarter valued at approximately $2,719,000. Bank of America Corp DE acquired a new position in Pulse Biosciences during the second quarter worth approximately $40,115,000. Jupiter Topco LLC acquired a new position in Pulse Biosciences during the second quarter worth approximately $241,000. Finally, Osterweis Capital Management Inc. purchased a new position in Pulse Biosciences during the second quarter worth approximately $28,000. Institutional investors and hedge funds own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a medical technology company developing bioelectric therapies based on its proprietary Nano-Pulse Stimulation (NPS) technology. The platform delivers short, nonthermal electrical pulses that temporarily affect cell membranes and are designed to selectively target unwanted cells while preserving surrounding tissue.

The company’s lead commercial product is the CellFX System, a dermatology platform designed to treat certain benign skin lesions and other dermatologic conditions using NPS technology.